BRPI0817478A2 - composição oralmente biodisponível, métodos para produzir uma composição oralmente biodisponível, e para tratar uma doença em um ser humano, e, kit. - Google Patents

composição oralmente biodisponível, métodos para produzir uma composição oralmente biodisponível, e para tratar uma doença em um ser humano, e, kit.

Info

Publication number
BRPI0817478A2
BRPI0817478A2 BRPI0817478A BRPI0817478A BRPI0817478A2 BR PI0817478 A2 BRPI0817478 A2 BR PI0817478A2 BR PI0817478 A BRPI0817478 A BR PI0817478A BR PI0817478 A BRPI0817478 A BR PI0817478A BR PI0817478 A2 BRPI0817478 A2 BR PI0817478A2
Authority
BR
Brazil
Prior art keywords
orally bioavailable
bioavailable composition
kit
disease
treating
Prior art date
Application number
BRPI0817478A
Other languages
English (en)
Inventor
Blair W Geho
John R Lau
Original Assignee
Sdg Inc An Ohio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sdg Inc An Ohio Corp filed Critical Sdg Inc An Ohio Corp
Publication of BRPI0817478A2 publication Critical patent/BRPI0817478A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
BRPI0817478A 2007-09-28 2008-09-26 composição oralmente biodisponível, métodos para produzir uma composição oralmente biodisponível, e para tratar uma doença em um ser humano, e, kit. BRPI0817478A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/904,937 US8962015B2 (en) 2007-09-28 2007-09-28 Orally bioavailable lipid-based constructs
PCT/US2008/077990 WO2009042945A1 (en) 2007-09-28 2008-09-26 Orally bioavailable lipid-based constructs

Publications (1)

Publication Number Publication Date
BRPI0817478A2 true BRPI0817478A2 (pt) 2015-09-08

Family

ID=40508640

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817478A BRPI0817478A2 (pt) 2007-09-28 2008-09-26 composição oralmente biodisponível, métodos para produzir uma composição oralmente biodisponível, e para tratar uma doença em um ser humano, e, kit.

Country Status (19)

Country Link
US (4) US8962015B2 (pt)
EP (2) EP2205217B1 (pt)
JP (2) JP2010540559A (pt)
KR (2) KR20160005130A (pt)
CN (2) CN101917971A (pt)
AU (3) AU2008304269B2 (pt)
BR (1) BRPI0817478A2 (pt)
CA (1) CA2704712C (pt)
DK (1) DK2205217T3 (pt)
ES (1) ES2661325T3 (pt)
HK (1) HK1211205A1 (pt)
HU (1) HUE037002T2 (pt)
LT (1) LT2205217T (pt)
MX (1) MX337138B (pt)
NO (1) NO2205217T3 (pt)
PL (1) PL2205217T3 (pt)
PT (1) PT2205217T (pt)
WO (1) WO2009042945A1 (pt)
ZA (1) ZA201002177B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US9145453B2 (en) * 2007-09-28 2015-09-29 Sdg, Inc. Orally bioavailable lipid-based constructs
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
WO2010069906A1 (en) * 2008-12-16 2010-06-24 Solvay Fluor Gmbh Metal parts containing a protective coating
US20120046224A1 (en) 2009-03-12 2012-02-23 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
US8753608B2 (en) 2010-08-24 2014-06-17 Canon Kabushiki Kaisha Complex and contrast agent for photoimaging using the same
EP2778221B1 (en) 2011-02-07 2017-07-26 Life Technologies Corporation Compositions and methods for stabilizing susceptible compounds
EP2717856B1 (en) 2011-05-10 2016-11-23 The Penn State Research Foundation Ceramide anionic liposome compositions
RS57519B1 (sr) 2011-11-02 2018-10-31 Keybioscience Ag Mimetici kalcitonina za lečenje bolesti i poremećaja
JP6170933B2 (ja) 2011-11-02 2017-07-26 キーバイオサイエンス・アクチエンゲゼルシャフト ペプチドの使用
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
JP5914418B2 (ja) * 2013-06-26 2016-05-11 富士フイルム株式会社 脂質粒子、核酸送達キャリア、核酸送達キャリア製造用組成物、脂質粒子の製造方法及び遺伝子導入方法
SI3068796T1 (en) 2013-11-14 2018-05-31 Keybioscience Ag Calcitonin mimetics for the treatment of diseases and disorders
CN104840415B (zh) * 2014-02-19 2019-03-15 香港浸会大学 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
US11464748B2 (en) * 2016-02-01 2022-10-11 Emory University Particles for targeted delivery and uses in managing bleeding or blood clotting
EP3426306A1 (en) * 2016-03-07 2019-01-16 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
MX2019010852A (es) * 2017-03-13 2019-10-30 Sdg Inc Nanoparticulas a base de lipidos con estabilidad mejorada.
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
CA3086771A1 (en) * 2018-01-05 2019-07-11 Sdg, Inc. Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
WO2020210697A1 (en) 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
MX2023006188A (es) * 2020-11-27 2023-07-13 D&D Pharmatech Inc Conjugado de material biologicamente activo que tiene acoplado un resto de biotina, un resto de acido graso o una combinacion de estos.
CN116940384A (zh) * 2020-11-27 2023-10-24 D&D制药技术股份有限公司 具有与生物素部分、脂肪酸部分或其组合偶联的生物活性材料缀合物的口服制剂
AU2024332624A1 (en) * 2023-08-28 2026-02-12 Signpath Pharma Inc. Cardioprotective lipids and methods of use

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4740375A (en) * 1985-02-25 1988-04-26 Technology Unlimited, Inc. Gelcores
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
GB8522963D0 (en) 1985-09-17 1985-10-23 Biocompatibles Ltd Microcapsules
US5000960A (en) 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
EP0395765A4 (en) * 1988-01-13 1991-09-25 Dainippon Pharmaceutical Co., Ltd. Oozing-proof liposome preparation
EP0577146A3 (en) 1988-05-16 1994-02-02 NeXstar Pharmaceuticals, Inc. Liposomes coupled to hormones
JP2792702B2 (ja) * 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 乾燥時に改善された安定性を示すリポソームの調製方法
DE3919982A1 (de) 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
US5104661A (en) 1989-08-14 1992-04-14 Technology Unlimited, Inc. Reverse loading of liposomes
JP2599492B2 (ja) 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
JPH0712424B2 (ja) 1991-06-21 1995-02-15 太陽化学株式会社 リポソーム
US5567432A (en) 1991-08-02 1996-10-22 Lau; John R. Masking of liposomes from RES recognition
US5420108A (en) 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
US5411730A (en) 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
GB9426484D0 (en) 1994-12-08 1995-03-08 Ciba Geigy Ag Compositions
US6004583A (en) 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
DE69736385T2 (de) 1996-02-09 2007-08-23 Pi-Wan Cheng Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6565889B2 (en) 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
FR2764508B1 (fr) * 1997-06-11 2000-10-20 Lipogel Sarl Nouveaux vecteurs liposomaux de principes actifs
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
JP2000516641A (ja) * 1997-07-02 2000-12-12 エスディージー インコーポレイテッド 診断および治療用途の目標指向性リポソーム構成物
EP1009383A1 (en) * 1997-09-04 2000-06-21 Biozone Laboratories, Inc. Oral liposomal delivery system
JPH11116478A (ja) 1997-10-08 1999-04-27 Taisho Pharmaceut Co Ltd 肥満防止剤
NZ504847A (en) * 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6573101B1 (en) 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
US7871641B2 (en) * 1998-05-19 2011-01-18 Sdg, Inc. Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
WO1999059545A1 (en) 1998-05-19 1999-11-25 Sdg, Inc. Targeted liposomal drug delivery system
WO1999065467A1 (en) 1998-06-16 1999-12-23 See Jackie R Method for introducing a chemical agent into the systemic circulation
EP1039880A1 (en) 1998-10-23 2000-10-04 Idea Innovative Dermale Applikationen GmbH Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
AU1921900A (en) * 1998-12-01 2000-06-19 Sdg, Inc. A polysome
WO2000062758A1 (en) 1999-04-16 2000-10-26 Osel, Inc. A method for improving the half-life of soluble viral-specific ligands on mucosal membranes
CN1561968A (zh) 1999-04-23 2005-01-12 三菱化学株式会社 与抗体和聚亚烷基二醇结合的脂质体
CN1221283C (zh) * 1999-05-19 2005-10-05 沈阳药科大学 口服胰岛素微粒剂及其制备方法
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
AU2002232394A1 (en) 2000-10-27 2002-05-27 Wayne State University Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis
CA2431212A1 (en) 2000-12-27 2002-07-25 Richard T. Wyatt Immunogenic proteoliposomes, and uses thereof
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
US7271008B2 (en) 2002-07-15 2007-09-18 Alton David Floyd Quality control of assays
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7132122B2 (en) 2002-10-30 2006-11-07 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using UV light and selected uses thereof
US20050026826A1 (en) 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US9872890B2 (en) 2003-03-19 2018-01-23 Paul C. Davidson Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
US7214545B2 (en) 2003-04-28 2007-05-08 The Regents Of The University Of California Element-coded affinity tags
CN103585136A (zh) 2003-05-20 2014-02-19 约翰霍普金斯大学 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物
EP1664784A1 (en) 2003-09-17 2006-06-07 Guava Technologies, Inc. Compositions and methods for analysis of target analytes
EP1684724A4 (en) 2003-11-19 2008-04-02 Barnes Jewish Hospital IMPROVED DRUG DELIVERY
US20050202075A1 (en) 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
WO2006127360A2 (en) * 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of interferon to a mammal
US20070218117A1 (en) 2006-03-20 2007-09-20 Sdg, Inc. Supra molecular construct for delivery of interferon to a mammal
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
WO2006127361A2 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
CN1895224A (zh) * 2006-06-26 2007-01-17 裴泽军 多烯磷脂酰胆碱脂质体制剂及其制备方法
US9814672B2 (en) 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
US9145453B2 (en) 2007-09-28 2015-09-29 Sdg, Inc. Orally bioavailable lipid-based constructs
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
GB2477545B (en) 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
US20120231069A1 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
MX2016000448A (es) 2013-07-17 2016-05-12 Araim Pharmaceuticals Inc Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
MX2019010852A (es) 2017-03-13 2019-10-30 Sdg Inc Nanoparticulas a base de lipidos con estabilidad mejorada.
CA3086771A1 (en) 2018-01-05 2019-07-11 Sdg, Inc. Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
WO2020210697A1 (en) 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Also Published As

Publication number Publication date
US20250288521A1 (en) 2025-09-18
LT2205217T (lt) 2018-03-26
US20200405638A1 (en) 2020-12-31
PT2205217T (pt) 2018-03-15
ZA201002177B (en) 2011-06-29
US10568835B2 (en) 2020-02-25
PL2205217T3 (pl) 2018-05-30
CA2704712C (en) 2016-05-31
AU2008304269B2 (en) 2015-07-09
EP3360540A1 (en) 2018-08-15
EP2205217A4 (en) 2013-01-23
US20150125518A1 (en) 2015-05-07
MX2010003396A (es) 2010-11-12
CN101917971A (zh) 2010-12-15
JP2015044883A (ja) 2015-03-12
HUE037002T2 (hu) 2018-08-28
AU2008304269A1 (en) 2009-04-02
EP2205217A1 (en) 2010-07-14
NO2205217T3 (pt) 2018-05-12
US20090087479A1 (en) 2009-04-02
KR20100109896A (ko) 2010-10-11
AU2015238887B2 (en) 2017-07-06
MX337138B (es) 2016-02-02
HK1211205A1 (en) 2016-05-20
WO2009042945A1 (en) 2009-04-02
EP2205217B1 (en) 2017-12-13
KR101747433B1 (ko) 2017-06-14
JP6066982B2 (ja) 2017-01-25
US11517529B2 (en) 2022-12-06
AU2015238887A1 (en) 2015-10-29
DK2205217T3 (en) 2018-03-12
ES2661325T3 (es) 2018-03-28
CA2704712A1 (en) 2009-04-02
AU2017239513A1 (en) 2017-10-26
CN104666246A (zh) 2015-06-03
JP2010540559A (ja) 2010-12-24
US8962015B2 (en) 2015-02-24
KR20160005130A (ko) 2016-01-13

Similar Documents

Publication Publication Date Title
BRPI0817478A2 (pt) composição oralmente biodisponível, métodos para produzir uma composição oralmente biodisponível, e para tratar uma doença em um ser humano, e, kit.
BRPI0814503A2 (pt) composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0814299A2 (pt) Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0819642A2 (pt) Método para a formação de uma dentadura para um paciente em uma única visita, e, dentadura
BRPI0905733A2 (pt) "composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0808163A2 (pt) Composição para aplicação tópica, métodos para tratar uma condição de superfície em um indivíduo, para preparar uma composição, e para usar o kit, e, kit
BRPI0814102A2 (pt) Implante pélvico, e, kit.
BRPI0813318A2 (pt) implante pélvico, e, kit
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0814688A2 (pt) composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica
BRPI0820474A2 (pt) método de tratamento de uma doença, uso de composto, e, composto
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0812245A2 (pt) Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica na forma sólida
BRPI0811228A2 (pt) Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0816904A2 (pt) Formas sólida, amorfa e cristalina, composição farmacêutica, e, método para tratar uma doença
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
BRPI1007211A2 (pt) composição farmacêutica oral em uma forma sólida, e, processo para preparar uma composição.
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
NL1031626A1 (nl) Verbindingen die bruikbaar zijn in therapie.
GB0707208D0 (en) Novel disease treatments

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.1 NA RPI NO 2478 DE 03/07/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.